|  |  |
| --- | --- |
| Intervention | **098. Breast Enlargement Surgery** |
| For the treatment of | Abnormal/absent breast development |
| Commissioning Position | This intervention is not routinely commissioned and therefore should not be offered to patients. Application for funding approval can be made, using the IFR process, by the clinician recommending the intervention, if their assessment is that there are exceptional reasons why their patient could benefit from it.    This policy does not cover the following where separate guidance is available:   * Gender reassignment surgery * Surgery for breast cancer |
| Summary of Rationale | Breast augmentation should not be carried out for “small” but normal breasts or for breast tissue involution (including postpartum changes).  Breast implants may be associated with significant morbidity and the need for secondary or revisional surgery (such as implant replacement) is common. In fact, it is estimated that one in three women will require further surgery within 10 years of their initial operation. It should be noted that not all patients demonstrate improvement in psychosocial outcome measures following breast augmentation. |
| References | [Breast enlargement (implants) - NHS](https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery/breast-enlargement/)  [Information for commissioners of plastic surgery services (BAPRAS)](https://bapras.org.uk/docs/default-source/commissioning-and-policy/information-for-commissioners-of-plastic-surgery-services.pdf?sfvrsn=ba572cc3_2) |
| Effective from | January 2025 |
| Policy Review Date | January 2028 |